Loading…
Budesonide bests COVID-19
Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide tw...
Saved in:
Published in: | Canadian family physician 2022-05, Vol.68 (5), p.355-355 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 355 |
container_issue | 5 |
container_start_page | 355 |
container_title | Canadian family physician |
container_volume | 68 |
creator | Moe, Samantha S Allan, G Michael Train, Anthony |
description | Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide twice a day for 14 days. Compared with usual care, budesonide shortened the time to recovery, increased the proportion of patients recovering by day 14, and reduced the need for health services. Outpatients with COVID-19 have a growing number of treatments available to them. Antiviral agents (nirmatrelvir-ritonavir) and monoclonal antibodies (eg, sotrovimab) appear to reduce the risk of death or hospitalization, but patient eligibility and access vary by jurisdiction. Family physicians can provide inhaled budesonide at the point of care to those not eligible for antiviral agents or monoclonal antibodies. Fluvoxamine is also available, but its benefits are less certain than those of other treatments. |
doi_str_mv | 10.46747/cfp.6805355 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9097727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2664797470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-dc42b847b39df6546a07529c52257fb8fdc63b335c84d5ba06fcdff40f03c1d93</originalsourceid><addsrcrecordid>eNpdkDtLA0EURgdRTIx2NjYSsLFw4533TiNofAUCaVTsht156IbNbrKTFfz3TkwMajXFHA73OwgdYxgwIZm8NH4-EClwyvkO6mKJecIJT3dRFwDShHJ47aCDEKYARDCK91EnopwQzLro5Ka1LtRVYV0_d2EZ-sPJy-g2weoQ7fmsDO5o8_bQ8_3d0_AxGU8eRsPrcWKoUMvEGkbylMmcKusFZyIDyYky0c-lz1NvjaA5pdykzPI8A-GN9Z6BB2qwVbSHrtbeeZvPnDWuWjZZqedNMcuaT11nhf77UxXv-q3-0AqUlERGwflG0NSLNm7QsyIYV5ZZ5eo2aCIEkyqWgoie_UOnddtUcd6K4likiq-oizVlmjqExvntMRj0d3Mdm-tN84if_h6whX8i0y99pHqb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2665168950</pqid></control><display><type>article</type><title>Budesonide bests COVID-19</title><source>PubMed Central</source><creator>Moe, Samantha S ; Allan, G Michael ; Train, Anthony</creator><creatorcontrib>Moe, Samantha S ; Allan, G Michael ; Train, Anthony</creatorcontrib><description>Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide twice a day for 14 days. Compared with usual care, budesonide shortened the time to recovery, increased the proportion of patients recovering by day 14, and reduced the need for health services. Outpatients with COVID-19 have a growing number of treatments available to them. Antiviral agents (nirmatrelvir-ritonavir) and monoclonal antibodies (eg, sotrovimab) appear to reduce the risk of death or hospitalization, but patient eligibility and access vary by jurisdiction. Family physicians can provide inhaled budesonide at the point of care to those not eligible for antiviral agents or monoclonal antibodies. Fluvoxamine is also available, but its benefits are less certain than those of other treatments.</description><identifier>ISSN: 0008-350X</identifier><identifier>EISSN: 1715-5258</identifier><identifier>DOI: 10.46747/cfp.6805355</identifier><identifier>PMID: 35552214</identifier><language>eng</language><publisher>Canada: College of Family Physicians of Canada</publisher><subject>Antiretroviral drugs ; Antiviral drugs ; Bronchodilator Agents ; Budesonide - therapeutic use ; Clinical outcomes ; Clinical trials ; COVID-19 ; Family physicians ; Hospitalization ; Humans ; Monoclonal antibodies ; SARS-CoV-2 ; Steroids ; Tools for Practice</subject><ispartof>Canadian family physician, 2022-05, Vol.68 (5), p.355-355</ispartof><rights>Copyright College of Family Physicians of Canada May 1, 2022</rights><rights>Copyright © 2022 the College of Family Physicians of Canada 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097727/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097727/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35552214$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moe, Samantha S</creatorcontrib><creatorcontrib>Allan, G Michael</creatorcontrib><creatorcontrib>Train, Anthony</creatorcontrib><title>Budesonide bests COVID-19</title><title>Canadian family physician</title><addtitle>Can Fam Physician</addtitle><description>Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide twice a day for 14 days. Compared with usual care, budesonide shortened the time to recovery, increased the proportion of patients recovering by day 14, and reduced the need for health services. Outpatients with COVID-19 have a growing number of treatments available to them. Antiviral agents (nirmatrelvir-ritonavir) and monoclonal antibodies (eg, sotrovimab) appear to reduce the risk of death or hospitalization, but patient eligibility and access vary by jurisdiction. Family physicians can provide inhaled budesonide at the point of care to those not eligible for antiviral agents or monoclonal antibodies. Fluvoxamine is also available, but its benefits are less certain than those of other treatments.</description><subject>Antiretroviral drugs</subject><subject>Antiviral drugs</subject><subject>Bronchodilator Agents</subject><subject>Budesonide - therapeutic use</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>COVID-19</subject><subject>Family physicians</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Monoclonal antibodies</subject><subject>SARS-CoV-2</subject><subject>Steroids</subject><subject>Tools for Practice</subject><issn>0008-350X</issn><issn>1715-5258</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdkDtLA0EURgdRTIx2NjYSsLFw4533TiNofAUCaVTsht156IbNbrKTFfz3TkwMajXFHA73OwgdYxgwIZm8NH4-EClwyvkO6mKJecIJT3dRFwDShHJ47aCDEKYARDCK91EnopwQzLro5Ka1LtRVYV0_d2EZ-sPJy-g2weoQ7fmsDO5o8_bQ8_3d0_AxGU8eRsPrcWKoUMvEGkbylMmcKusFZyIDyYky0c-lz1NvjaA5pdykzPI8A-GN9Z6BB2qwVbSHrtbeeZvPnDWuWjZZqedNMcuaT11nhf77UxXv-q3-0AqUlERGwflG0NSLNm7QsyIYV5ZZ5eo2aCIEkyqWgoie_UOnddtUcd6K4likiq-oizVlmjqExvntMRj0d3Mdm-tN84if_h6whX8i0y99pHqb</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Moe, Samantha S</creator><creator>Allan, G Michael</creator><creator>Train, Anthony</creator><general>College of Family Physicians of Canada</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202205</creationdate><title>Budesonide bests COVID-19</title><author>Moe, Samantha S ; Allan, G Michael ; Train, Anthony</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-dc42b847b39df6546a07529c52257fb8fdc63b335c84d5ba06fcdff40f03c1d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiretroviral drugs</topic><topic>Antiviral drugs</topic><topic>Bronchodilator Agents</topic><topic>Budesonide - therapeutic use</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>COVID-19</topic><topic>Family physicians</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Monoclonal antibodies</topic><topic>SARS-CoV-2</topic><topic>Steroids</topic><topic>Tools for Practice</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moe, Samantha S</creatorcontrib><creatorcontrib>Allan, G Michael</creatorcontrib><creatorcontrib>Train, Anthony</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian family physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moe, Samantha S</au><au>Allan, G Michael</au><au>Train, Anthony</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Budesonide bests COVID-19</atitle><jtitle>Canadian family physician</jtitle><addtitle>Can Fam Physician</addtitle><date>2022-05</date><risdate>2022</risdate><volume>68</volume><issue>5</issue><spage>355</spage><epage>355</epage><pages>355-355</pages><issn>0008-350X</issn><eissn>1715-5258</eissn><abstract>Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide twice a day for 14 days. Compared with usual care, budesonide shortened the time to recovery, increased the proportion of patients recovering by day 14, and reduced the need for health services. Outpatients with COVID-19 have a growing number of treatments available to them. Antiviral agents (nirmatrelvir-ritonavir) and monoclonal antibodies (eg, sotrovimab) appear to reduce the risk of death or hospitalization, but patient eligibility and access vary by jurisdiction. Family physicians can provide inhaled budesonide at the point of care to those not eligible for antiviral agents or monoclonal antibodies. Fluvoxamine is also available, but its benefits are less certain than those of other treatments.</abstract><cop>Canada</cop><pub>College of Family Physicians of Canada</pub><pmid>35552214</pmid><doi>10.46747/cfp.6805355</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-350X |
ispartof | Canadian family physician, 2022-05, Vol.68 (5), p.355-355 |
issn | 0008-350X 1715-5258 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9097727 |
source | PubMed Central |
subjects | Antiretroviral drugs Antiviral drugs Bronchodilator Agents Budesonide - therapeutic use Clinical outcomes Clinical trials COVID-19 Family physicians Hospitalization Humans Monoclonal antibodies SARS-CoV-2 Steroids Tools for Practice |
title | Budesonide bests COVID-19 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T09%3A21%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Budesonide%20bests%20COVID-19&rft.jtitle=Canadian%20family%20physician&rft.au=Moe,%20Samantha%20S&rft.date=2022-05&rft.volume=68&rft.issue=5&rft.spage=355&rft.epage=355&rft.pages=355-355&rft.issn=0008-350X&rft.eissn=1715-5258&rft_id=info:doi/10.46747/cfp.6805355&rft_dat=%3Cproquest_pubme%3E2664797470%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-dc42b847b39df6546a07529c52257fb8fdc63b335c84d5ba06fcdff40f03c1d93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2665168950&rft_id=info:pmid/35552214&rfr_iscdi=true |